Uncategorized - November 1, 2015
Novo Nordisk invests in new facility
Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Denmark, creating 450 new jobs. The company is investing 2.1 billion Danish kroner in a new 10,300 m2 facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity. A groundbreaking ceremony marking the start of construction was held on […]
Careers article - October 5, 2015
Lars Rebien Sorensen tops best CEO ranking
The chief executive of Danish Novo Nordisk, Lars Rebien Sorensen, was top CEO in a new performance ranking. The Novo CEO topped Harvard Business Review’s list of the 100 best performing CEOs this year. He beat for example the CEO of Starbucks, Nike and the former CEO of Cisco Systems, John Chambers. The list evaluates […]
Uncategorized - September 15, 2015
New study about type 2 diabetes management
Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients’ and physicians’ perceptions of control differ, could benefit physician-patient communication and improve diabetes management. New findings from the Perceptions of Control (POC) study showed adults with type 2 diabetes uncontrolled on basal insulin had a […]
Acquisition - September 3, 2015
Novo to Acquire Calibrium and MB2
Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies. The two companies are based in Indiana, US, and Novo Nordisk’s acquisition will expand the company portfolio within diabetes and obesity. Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment […]
Pharma Business - August 6, 2015
Novo Nordisk reports increased operating profit
Novo Nordisk increased operating profit in Danish kroner by 57 percent in the first six months of 2015 to DKK 26.3 billion. 16% local currency operating profit growth adjusted for the NNIT divestment Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion. Sales of Victoza® increased by 41% […]
Intellectual Property - July 4, 2015
ITC Investigating Complaint Against Novo Nordisk
A complaint by Baxter back in March that Novo Nordisk’s recently launched hemophilia drug infringed on some of Baxter’s patents prompted an investigation this week by the U.S. International Trade Commission. On Wednesday, Novo Nordisk disputed Baxter’s claims that its Novoeight used substances Baxter developed, Reuters reports, and it told the news service it had […]
